THC Pain-Behavior Effects and CBD Serum-Cytokine Changes Diverged in Rats

A change in an inflammatory marker is not automatically a change in pain. In rats with experimentally induced inflammation, THC and CBD showed different patterns across pain-related behavior, paw swelling and serum cytokines.

The experiment measured several domains

Researchers used an inflammatory-pain model and repeated THC, CBD or vehicle treatment. Outcomes included mechanical and thermal responses, weight bearing, movement and hindpaw edema. A related experiment measured cytokines in serum, a specific processed blood matrix.

Positive and null results pointed in different directions

The abstract reports dose-related reduction of pain-related behaviors with THC, little tolerance over the short regimen and no reduction in paw edema. CBD's effects on pain-related behavior were minimal, although several serum cytokines changed. THC produced little or no change in the measured serum cytokines.

The measurements are not substitutes

Pain-related behavior can improve without a detectable reduction in swelling or the selected circulating markers. Conversely, a cytokine change does not demonstrate meaningful analgesia. Serum measurements also cannot identify every local tissue process or be treated as a measure of THC-related intoxication.

Few sex differences in drug effects were reported, while the inflammatory immune response itself was greater in males in the relevant comparisons. This is a short-term rat study, not proof of comparative efficacy in patients. The defensible interpretation preserves the separate outcomes instead of giving either cannabinoid a single global label such as anti-inflammatory, analgesic or ineffective.

Related: interpreting cannabis tolerance claims.

Research cited

Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain. The Journal of pharmacology and experimental therapeutics (2020). doi:10.1124/jpet.119.263319. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

A 2021 pilot study reported strong initial antinociceptive responses to THC and cannabinolic acid, followed by decreasing responses over subsequent days. The evidence concerns adult male mice and experimental mechanical and thermal tests. The study evaluated two nociceptive domains Mechanical and thermal responses were assessed after systemic intraperitoneal administration. Those…

Spread the love

Read Article: A Pilot Mouse Study Found Declining THC and CBNA Antinociception With Repeated Administration

Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A 2001 mouse study found different opioid- and cannabinoid-receptor protein patterns across midbrain and spinal cord after short-term THC–morphine treatment. A statement about total receptor change would obscure those tissue-specific comparisons. The comparison included separate treatment groups Investigators assessed THC, morphine and their combination using Western blot measurements. Opioid-receptor protein…

Spread the love

Read Article: Short-Term THC–Morphine Treatment Produced Different Receptor-Protein Patterns in Mouse Midbrain and Spinal Cord

A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

A 2003 study found that selected kinase inhibitors reversed THC antinociceptive tolerance while others did not. One higher-dose intervention reduced THC's acute antinociceptive effect, illustrating a different outcome from reversing tolerance. The panel included useful negatives The study tested interventions directed at several kinases. Some did not affect tolerance under…

Spread the love

Read Article: A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us